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Indoleamine 2,3-dioxygenase (IDO;E C: 1.13.11.52)i s ah eme containing enzyme that catalyzes the oxidative cleavage of L-Tryptophan (L-Trp) in the first and rate-limiting step of the kynurenine pathway to produce N-formylkynurenine.
[1] Twoi soformso ft his enzyme have been characterized,n amely IDO1 and IDO2, sharing~43 %s equence identity and being endowed with distinct biochemical features.
[2] Althougha nother structurally unrelated enzyme, tryptophan 2,3-dioxygenase (TDO), has also been reported to be able to catalyzet he same reaction,i ti sI DO1 that has attracted ag reat deal of attention since its discoverya sk ey regulator of immunosuppressive pathwaysi nm aternal tolerance towardt he allogenic fetus and in tumor immunoediting process. [3] This interest has fostered the development of several classes of IDO1 inhibitors as anticancer agents with the aim of enhancing the efficacy of current chemotherapeutic drugs in combination therapies. [4] Of these, few IDO1 inhibitors have nowadays reached the clinical stageo fd evelopment including NLG919 (1, Figure 1 ), INCB024360 (2)a nd D-1-Methyl-Trp (3) [5] albeit this latteri sn om ore considered ab ona fide IDO1i nhibitor. [6] In 2006, the results of crystallographic studieso nh uman IDO1 disclosed for the first time the structural features of the enzyme and provided clues on the bindingm ode of inhibitors (pdb code:2 D0T). [7] Specifically,I DO1 folds into two distinct domains:t he large domain and the small domain. Thef ormer is composed of fifteen a-helices and containst he catalytic site, wherein the heme group is bound to residue His346 by the fifth coordination site of the iron atom. Al ong flexible loop (360-380,n ot solved in the crystal structures) is located at the entranceo ft he catalytic site definingachannel that runs parallel to the heme plane. Coarse grainings imulation studies suggested the involvement of this loop in controllingt he shuttlingo fs ubstrate and products into the catalytic pocketo fI DO1. [8] The small domain of the enzyme is composed of nine a-helices and two b-sheets, and contains two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located at residues 103-120 and 241-258, respectively.I TIMs are substrates of kinase-mediated phosphorylation, promoting the interaction with the suppressor of cytokine signaling-3 (SOCS3) and taggingI DO1 to the ubiquitin-proteasome mediated degradation. [9] The small domain is connectedt ot he large domain by af lexible loop (residues 260-265) that also contributest od efinet he shape of the catalytic site.
Of note, the crystal structure of IDO1i nc omplex with 4-phenylimidazole (4PIM, 4)s howed the inhibitor binding to Abstract:I nt he last decade, indoleamine 2,3-dioxygenase 1( IDO1) hasa ttractedagreat deal of attentionb eing recognized as key regulator of immunosuppressive pathways in the tumor immuno-editingp rocess. Several classes of inhibitors have been developed as potential anticancer agents, but only few of them have advanced in clinical trials. Hence, the quest of novel potent and selectivei nhibitors of the enzyme is still activea nd mostly pursued by structure-based drugd esign strategies based on early and more recentc rystal structureso fI DO1. Combining docking studies and molecular dynamics imulations, in this work we have comparatively investigatedt he structuralf eatures of each crystals tructure of IDO1. The results pinpoint different features in specific crystals tructures of the enzymet hat may benefit the medicinal chemistrya rena aiding the design of novel potent and selective inhibitors of IDO1.
the sixthc oordination site of the iron-heme, as well as the presenceo ft wo additional molecules from the crystallization buffer,n amely 2-(N-cyclohexylamino)ethanes ulfonic acid (CHES, 5), bindingt othe enzyme (Figure 2A ). The presence of these molecules was suggested to define an accessory site wherein substrate, enhancer or uncompetitive inhibitors could bind to the protein. [8] The above structure of IDO1 was instrumental to develop several structure-based drug design (SBDD)a pproaches as well as to guide hit to lead (H2L) optimization efforts of inhibitors. [10, 11] Recently,a dditional crystallographic studies have beenc arried out on IDO1 bound to largeri nhibitors than 4PIM (pdb codes:4 PK5, 4PK6). [12] The results have shown additionalf eatures of the enzyme, including the existence of two additional pockets into the catalytic cleft that were in part anticipated as result of previous structureactivity relationship studies of IDO1 inhibitors. [11] Specifically,t he two accessory binding pockets resultf rom inhibitorinducedc onformational rearrangements of the enzyme which further expand the volumeo ft he catalytic site ( Full Paper www.molinf.com ure 2B-C). The first pocket (pocket A) is localized above the sixth coordination site of the iron-heme protrudingi nto the small domain, whereast he second pocket (pocket B) is located at the entrance of the channel to the catalytic site including residues that were recognizedf undamental for IDO1 activity by mutagenesis experiments sucha sA rg231, Phe226 and Phe227. [7] Althought his observation suggests that multiple conformations of thee nzyme may affect to different extent the molecular recognition of inhibitors by shaping the volume of the catalytic site of IDO1, the conformational properties of IDO1h aveo nly in part been investigated with coarse grainings imulations or molecular dynamic (MD) simulations mostly usedt os tudy the catalytic mechanismo fthe enzyme.
Since the structure of IDO1 bound to 4PIM (4)w as almost exclusively used for SBDD and H2L approaches, the aim of this work was to assesst he extent of value that recent crystals tructureso fIDO1 may bring in the medicinal chemistrya rena for designing novel potent inhibitors of the enzyme. Specifically,i nt he first part of the work, we usedself-and cross-docking studies to comparatively investigate the abilityt op redict the correct binding modes of co-crystallized IDO1 inhibitors. In the second part, we used molecular dynamic (MD) simulations to investigate the stability of the binding posesr esulting from docking studies in the three crystal structures, and then evaluate whether the structural features of the catalytic cleft observed in the more recent 4PK5 and 4PK6 entries could be somehow anticipated using the early structure of the enzyme in complex with4PIM (4).
2Materials and Methods

Docking Studies
Three IDO1 crystal structures (PDB codes:2 D0T,r esolution = 2.30 ;4 PK5, resolution = 2.79 ;4 PK6,r esolution = 3.45 ) [7, 12] were downloaded fromt he Protein Data Bank, [13] and their chain Awas prepared(addition of hydrogens, ionization statesa tp H7.0, optimization and minimization of the structure) with the Protein PreparationW izard,t ool of Maestro 10.1 (Schrçdinger Inc.). The unsolved loop 361-379 was reconstructed with Prime3 .9. [14] The iron was set as Fe III becauseo fe xperimental suggestionsi ndicating that imidazole-based molecules have greatera ffinity for the oxidized form of the enzyme. [15] Ligands were prepared with LigPrep 3.3 generating all ionization states at pH 7 AE 2. [17] Docking studiesa nd inducedf it docking (IFD) studies were carried out using Glide 6.6 and standard precision (SP) mode, storing the best ten scored binding poses for each molecule as output. In both docking and IFD studies, grids were defined in the same way,g enerating one grid for each crystal with the centre locatedo nt he centre of mass of the co-crystallized ligand. The inner grid box was sized 12 12 12 . Only for 2D0T,asecond differentgrid wasgenerated retaining the two crystallized molecules of CHES (5) . All rotatable groups of residues inside the outer box were taken into account. [16] In the IFD procedure, the side chains of binding site residuesw ithin5 of the co-crystallized ligand were selected for conformational searches. All other docking and IFD parameters were set on the relative default values. All stored binding poses from docking and IFDs tudies were inspected in ordert of ind the most reliable ones, evaluating the root mean square deviation (RMSD) of heavy atoms from the relative experimental ligand bindingp ose and distances of interaction to the iron. Solvent accessible surface areas (SASA) of binding sites in 2D0T,4 PK5 and 4PK6 were calculated rolling asphere of radius 1.4 (Connolly surface) around binding site residues defined as those residues falling within 5 of co-crystallized ligand. Figure 3w as generated using VMD surf drawing method on binding site residues of 2D0T,4 PK5 and 4PK6.
Molecular DynamicSimulations
MD simulations were run using ACEMD (Accelera Ltd) [18] and CHARMM36 force field. The most reliable binding poses from docking studies weres elected as starting struc-SPECIAL ISSUE ture. Atomic chargeso ft he heme groupw ere calculated using quantum mechanicsw ith Jaguar8 .7,D FT theory and 6-31G* basis set. During these calculations, Fe III -heme bound to the basic nitrogen of methyl-imidazole was used to mimic the heme-His346 interaction. [19] Ligands were parameterized with ParamChemTool.
[20] The protein-ligand complex was solvatedi nacubic box using TIP3P water molecules, extended 12 awayf rom any protein atom. The system was neutralized addingaconcentrationo f0.15 Mo f chlorine and sodium ions and periodic boundary conditions were used. Cut-offo fn on-boded interactions was set to the valueo f9.E nergy minimizationo f1 000 iterations was conducted before 1nsp ositional constrained equilibration. Then, 1.5 ns equilibration without constraintsw as performed using slow increasing of temperature (10 degrees every 50 ps, 0t o3 00 8K) to avoid jumps of the "hinge" loop (260-265). Finally,a2 0nss imulation was run, in NPT condition, sampling every 500 ps (200 totalf rames). The results were visualized with VMD software and analysed with tcl scripting. [21] In particular,h ydrophobic contacts were considered for hydrophobic side chain falling within 4 of aromatic and/or aliphatic carbons of the ligand, while hydrogen bondsw ere calculated using the H-bondsp lugin of VMD definingt he following distance and angle cut-off criteria:c ut-off distance value of 3 ,c ut-offa ngle value of 30 degree.
3Results and Discussion
Docking Studies
Self-and cross-docking studies of 4PIM (4), thiazolotriazole derivative( 6)a nd imidazothiazole derivative (7)w ith and without the induced fit docking procedure (IFD) were carried out into the crystal structureso fI DO1 (pdb codes: 2D0T,4 PK5, 4PK6) using Glide as reported in the method section. Ta ble 1r eports the best results in termso fs coring function (G-score), root mean square deviation (RMSD-xray) from the experimental binding pose, and distance of the coordinating nitrogen atom to the iron-heme (d N -Fe )a mong the top ten ranked solutions (see supplementary materials, Ta ble S1-S10). As ag eneral consideration, the inspection of the table reveals that self-and cross-IFDs tudies do not provide any betters olution than self-and cross-docking in terms of closeness to the experimental binding pose.
Dockings tudies into 2D0T provide ar eliable binding pose only for 4PIM (self-docking approach; 4 RMSD-xray = 0.70 ,d N-Fe = 2.53 ), while ar emote bindingp ose is obtained for thiazolotriazole derivative (cross-dockinga pproach; 6 RMSD-xray = 5.09 ,d N-Fe = 6.49 )a nd solutions are foundf or the imidazothiazole derivative (7)o nly when using the IFD procedure (cross-IFD approach), albeit with ap oor RMSD-xray value (Figure 4 ). This observationi sv ery likely ascribed to the smaller size of the catalytic pocket observed in 2D0T with respect to 4PK5 and 4PK6 (Figure 3) , which hampers the fit of the large molecular shape of the thiazolotriazole derivative (6,M W = 425) and the imidazothiazole derivative (7,M W= 396) by generatings teric clashes with the pocket.
Next, we investigated whether the presence of the two CHES molecules observed in 2D0T could affectt he binding pose of 4PIM (4)i nd ockings tudies. As ar esult, it is found that the docking of compound 4 into the catalytic cleft of IDO1 containing CHES molecules provides am ore reliable bindingp ose of the inhibitor,w ith lower d N-Fe (2.29 )a nd improved RMSD value (RMSD-xray = 0.34 ). In agreement with the interactions observed in 2D0T,t he distal nitrogen of the imidazole ring of 4PIM is here placed above the sixth coordination site of the iron-heme, with the phenyl group making hydrophobic contacts with Val130, Leu234a nd Ala264, and p-p interactions with Tyr126, Phe163 and Phe164 (Figure4). Interestingly,C HES molecules (5)s eem to favour the predictiono ft he correct binding pose of 4PIM (4)t ot he enzyme, witho ne of them (NHE502) pack-SPECIAL ISSUE ing the small inhibitor( 4,M W= 144) into the catalyticc left in hydrophobic contacts. Docking of compounds 4, 6 and 7 into 4PK5 and 4PK6 yield solutions for all of the inhibitors, in line with the larger size of the catalytic pocket (Figure 3 ). In the case of 4PK5, results of compound 6 show ag oodr eproduction of the experimental bindingp ose (self-docking approach; 6 RMSD-xray = 0.31 ,d N-Fe = 2.41 ). In particular, the distal nitrogen atom of the thiazolotriazole moiety is placed above the sixthc oordination site of the iron-heme, with the p-toluene groupp rotruding into ah ydrophobic cage of pocket Aw hich is formed by the side chains of residues Tyr126, Cys129, Val130,P he163, Phe164, Leu234 and Ala264. Moreover,a ne xtended conformation of the benzodioxane side chain engages Phe226, Phe227, Ile354a nd Leu384 with hydrophobic contacts and Arg231w ith ah ydrogen bond in pocket B( Figure 5A ). Docking studies of 4PIM (4)a nd 7 yield binding poses that are slightly different from the experimental ones (cross-dockinga pproach; 4 RMSD-xray = 1.13 ,d N-Fe = 2.80 ; 7 RMSD-xray = 1.36 , d N-Fe = 2.54 ). Specifically,4 PIM is still placed with its distal nitrogen of the imidazole ring above the sixth coordination site of the iron-heme, while the phenyl moiety mostly interacts with Val130, Tyr126, Phe163, Phe164, Leu234 and Ala264 ( Figure 5B ). Compound 7 engages the sixth coordination site of the iron-hemew ith its basic nitrogen of the imidazothiazole moiety and occupies the hydrophobic pocketA with the p-tolueneg roup.A ccording to this docked pose, an extended conformation of the m-chlorine benzyls ide chain projects towards pocket B, making a p-p interaction with Phe226 and hydrophobic contactsw ith Leu384( Figure 5C ).
Using 4PK6,c ompound 7 shows the binding pose closest to the experimental binding mode (self-docking approach; 7 RMSD-xray = 0.32 ,d N-Fe = 2.46 ), whereas compounds 4 again displaysabindingp ose that is slightly different from the experimentalo ne (cross-dockinga pproach; 4 RMSDxray value = 1.27 ,d N-Fe = 2.77 ). Of note, the docked SPECIAL ISSUE pose of compound 6 is markedly different from the binding mode observed in the relative crystal structure (cross-docking approach; 6 RMSD-xray = 2.51 ,d N-Fe = 2.82 ). It is noteworthy that specific conformational rearrangements of binding site residues Phe226 and Arg231 in 4PK6 may force compound 6 to adopt ad iverse binding pose in docking studies, thereby accountingf or the higherR MSD-xray value.
Hence, in agreement with crystallographic data, the distal nitrogen atomo ft he imidazothiazole moiety of 7 is correctly placed abovet he sixth coordination site of the iron-heme, whereas the p-tolueneg roup is inserted into pocket Ai nteracting with Tyr126, Cys129, Val130, Phe163, Phe164, Leu234 and Ala264. The m-chlorine benzyl side chain is harboured into pocketB through a p-cation interaction with Arg231 ( Figure 6A ). Establishing a p-cation interaction,t he specific conformationo fA rg231 in 4PK6 constrains the benzodioxane side chain of 6 into af olded conformationt hat is not in agreement with the experimental data of 4PK5 ( Figure 6B ). 4PIM (4)i sa gain placed with its imidazoler ing on the sixth coordination site of the ironheme, albeit the phenyl moiety adopts as lightly different orientation into pocket Aw ith respect to the one observed in 2D0T ( Figure 6C ).
Molecular Dynamics
MD simulations were carried out to assess the stability of selected binding posesa so btained from self-and crossdocking studies. Results were also compared to the stability of the experimental bindingp oses of compounds 4, 6 and 7 as observed in 2D0T,4 PK5 and 4PK6, respectively. Accordingly,atotal of 13 MD trajectories were generated and analyzed calculating the RMSD of heavy atomso ft he ligands from the relative starting pose and the distance of the coordinating nitrogen atom to the iron-heme( d N-Fe ) over the 20 ns MD simulations (Table 1) As ag eneral consideration, MD simulations of crystal structures reveal strong stability of the experimental binding modes for compounds 4, 6 and 7,s uggesting that the adopted force field (CHARMM36), atomic charge parameterization and length of simulation (20ns) are adequate to study ligands interacting with the heme-containing binding site of IDO1. (Table 2 , occupancies 81 %-68 %,9 8% and 95 %-86 %), and Val130, Leu234 and Ala264 with favorable van der Waals contacts along the 20 ns MD simulations (Table 2 , occupancies 86 %-95 %,6 2%-78 %, and 85 %-97 %).
SPECIAL ISSUE
Results of 4PK5 simulations pinpoint againt he lack of stability of the bindingp ose obtainedf or 4PIM (4,d N-Fe = 9.33 AE 1.90 ,R MSD = 6.97 AE 2.14 ), whereas more stable binding poses are observed for the thiazolotriazole derivative (6,d N-Fe = 3.58 AE 1.08 ,R MSD = 1.09 AE 0.55 )a nd the imidazothiazole derivative (7, Table 2 , occupancies 91 %-59 %,8 3%-89 %, 31 %-63 %, 56 %) by the p-toluene group, and the presence of favourable hydrophobic contacts with Val130, Leu234, Ala264, Phe226, Ile354 and Leu384 (Table 2 , occupancies 63 %, 71 %-48 %, 66 %, 56 %, 75 %, 78 %-41 %). Of note, the stability of the hydrogen bond interaction betweent he oxygen of the benzodioxane moiety and Arg231 is clear in the MD trajectory of the ligand-bound complex resulting from selfdockings tudies (Table 2 , occupancy 29 %), while it seems unstable in the trajectory of the crystal structure whereini t is replaced by a p-cation interaction (Table 2, occupancy 22 %). Likewise, the binding mode of the imidazothiazole derivative (7)f rom the 4PK5 trajectory shows as table anchoring of the coordinating nitrogen to the iron-heme along the entire simulation (d N-Fe = 2.66 AE 0.29 ). The occurrence of hydrophobic and p-stacking interactions is observed between the p-toluene group and Tyr126, Phe163 and Phe164 (Table 2 , occupancies 98 %, 94 %, 40 %). The mchlorine benzyls ide chain interacts with Arg231 and Phe226 in pocketB,m aking p-cation and p-stacking interactions (Table 2 , occupancies 57 %a nd 70 %), respectively. Favourable van der Waals contactsa re also found between compound 7 and the side chains of Val130, Leu234, Ala264, and Ile354 (Table 2, Showingasimilar patterno fi nteractions to 4PK5 simulation, in 4PK6 trajectories the imidazothiazole derivative (7) engages Tyr126, Phe163 and Phe164 withh ydrophobic and p-stacking interactions in pocket A( Ta ble 2, occupancies 99 %-99 %, 97 %-98 %, 38 %-40 %), Arg231 and Phe226 with p-cation and p-stacking interactions in pocket B SPECIAL ISSUE ( Table 2 , occupancies 62 %-22 %a nd 74 %-52 %), and Val130,L eu234, Ala264 and Ile354w ith favourablev an der Waals contacts (Table 2 , occupancies 52 %-43 %, 88 %-82 %, 95 %-94 %, 32 %-94 %).
Discussion
Being acquainted with bioactive conformationa nd binding mode of al igand to its biological target is the cornerstone of any SBDD strategy and H2L approach. This can be achieved using experimental methods sucha sc rystallographic experiments and/or computational approaches including docking studies and molecular dynamic (MD) simulations. Compliant to this statement, the early disclosure of the crystal structure of IDO1 bound to 4PIM (4,p db code: 2D0T) enabled the designa nd development of potent and selectivei nhibitors of the enzyme. Successful examples include NLG919 (1)and INCB024360 (2), that are currently advancing in clinicalt rials as single therapy for solid tumor. [5] Recently,t wo additional crystal structures of IDO1 have been disclosed in complex withathiazolotriazole derivative (6,p db code:4 PK5) and imidazothiazole derivative (7,p db code:4 PK6),r espectively.T hese structures show different structural features with respect to the early ligand bound crystal structure of IDO1, includingt he absence of CHES ligands as observed in 2D0T,d ifferents ize of the catalytic pocket, and differentc onformations of Phe226 and Arg231 which also result in diverses hapes of the ligand binding SPECIAL ISSUE Figure 7 . Variation of the distance between the iron-heme (d N-Fe )a nd the coordinating nitrogen atom of 4PIM (4), thiazolotriazole derivative (6)and imidazothiazole derivative (7)a long the MD trajectories of 4PK5 (A) and 4PK6 (B).
cleft (Figure2). In ordert ou nderstand the added value and/or redundancy that these featuresm ay bring in the design and development of secondg enerationI DO1 inhibitors, we challenged the ability of each structure of IDO1 to reproduce the experimentalb inding modes of co-crystallized inhibitors using self-docking and cross-dockings tudies with and without the IFD procedure, and combined with MD simulations.
Results of self-dockings tudies show that all structures are able to recover the correct binding poses of co-crystallized inhibitors among the top ten ranked solutionsw hich are also stable in MD simulations with the only exception of 4PIM (4)d ockedi nto 2D0T( Ta ble 1, row 2). Conversely, poor solutionsa re generally obtained when the IFD procedure is adopted (see supplementary materials, Ta ble S1-S10) evidencing the fallacy of the IFD approach in finding appropriate conformational rearrangements of binding site residues that are able to resume correct binding poses of IDO1 co-crystallized ligands.
Moreover,a lthough the good stability of ligand-bound crystal complexes in MD trajectories (Table 1, ). Indeed,t hese structures provideb etter results in cross-docking studies than 2D0T, which is endowed with the smallest binding site volume (SASA = 327 2 ). Accordingly,t he use of 2D0T in cross-docking studiesy ields poor solutions for the thiazolotriazole derivative (6,R MSD-xray = 5.09 )a nd the imidazothiazole derivative (7,R MSD-xray = 5.73 ), being remotely located from the experimental binding modes. This structure of IDO1 could thus not anticipate the structuralf eatures observed in 4PK5 and 4PK6.
Structures 4PK5 and 4PK6 showa lso diverse shapes of the ligand binding cleft as ar esult of diverse conformations of Phe226 and Arg231 (Figure 2B-C) . These conformations remain rather stable alongt he MD trajectories, as evidenced by the low root mean square fluctuations (RMSF) of the relatives ide chains (Table 3) . Althoughi n4 PK6 the conformations of Arg231 and Phe226 do not remarkablyi nfluence cross-docking results, the stability of the obtained bindingp oses of 4PIM (4)a nd the thiazolotriazole deriva-SPECIAL ISSUE Figure 8 . Features of the catalytic cleft of IDO1 in 4U72 (A) and 4U74 (B). tive (6)i sp oor in MD simulations, as evidencedb yh igh average RMSD values.I nt he case of 4PIM (4)t his may also be ascribedt ot he lack of CHES molecules in the catalytic cleft, since ap oor stability of the binding pose of this ligand is also observed in 4PK5 and in self-dockings tudies using 2D0Tw ithout CHES molecules. In the case of crossdocking of thiazolotriazole derivative (6)i n4 PK6,t he conformationso fP he226a nd Arg231 provide steric bumps thath amper the correct positioning of the ligand into the catalytic cleft of IDO1. Conversely,t he extended conformation of Arg231 in 4PK5 seems to providet he best results in termso fc ross-dockings tudies of the imidazothiazole derivative( 7). In particular, the bioactive conformation of 7 bound to IDO1 as observed in the MD simulation of 4PK5 is very similar to that observed in the MD simulation of 4PK6, though as lightly differentp attern of interactions is also found (Table 2, Figure 9 ). This latter is due to the conformational plasticity of Phe226 that directly engages the m-chlorine benzyl side chain of 7 with as table p-p interaction in 4PK5 ( Figure 9A ), while it indirectly promotes a pcationi nteractionw ith Arg231 in the MD simulation of 4PK6 (Figure9B). Overall, this result suggests that the use of 4PK5 is able to predict the experimental bioactive conformation and binding modeo f7 in cross-dockings tudies combinedw ith MD simulations, whereas this does not hold true for 4PK6. As ac onsequence, 4PK5 may represent an unbiased structure of IDO1f or SBDDs trategy and H2L approach, enablingawider exploration of the chemical space than 4PK6 and 2D0T structures.
4C onclusions
IDO1 playsa ne ssential role as key regulator of immunosuppressive pathways in the tumori mmuno-editing process. Embracing this notion,alarge number of IDO1 inhibitors have been disclosed as potential anticancer agents in the last decade. The designo fm any of these compounds has been inspired by the availability of the early crystal structure of the enzyme in complex with 4PIM (4). Nevertheless, only few of these inhibitors have nowadays entered in clinicalt rials. As ac onsequence, the quest of novel potent and selective inhibitors of the enzyme is still active, and furtherf ostered by the recent availability of additional crystal structureso fI DO1. In this work, we have analyzed the extent of value and/orr edundancy that these new structures bring to the designa nd development of novel IDO1 inhibitors. Using self-and cross-docking studies combined with MD simulations, we have shown that 4PK5 and 4PK6 unveil unprecedented structuralf eatures of the enzyme thatc ould not be anticipated using 2D0T.F urthermore, the early 2D0T structure is somehow biased by the presenceo fC HES molecules that bind to the catalytic site and affect the binding mode of 4PIM (4)t ot he enzyme. Finally,t his study pinpoints4 PK5 structure as of interest for the application of SBDD strategya nd H2L development approach to design novel potenta nd selectivem odulators of IDO1.
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SPECIAL ISSUE Figure 9 . Bioactive conformation and binding mode of imidazothiazole derivative (7)i nto 4PK5 (A) and 4PK6 (B) along 20 ns MD simulations.
